AusperBio Secures $37 Million Series A Financing to Advance Functional Cure for Chronic Hepatitis B with Novel Oligonucleotide Therapy

Today, AusperBio (hereinafter referred to as "AusperBio") announced,Since securing RMB 100 million in a Pre-A+ round last November, the company has raised another USD 37 million (approximately RMB 269 million) in an A-round of financing.This round of financing was led by InnoPinnacle Fund with additional investment, and jointly participated by Vivo Capital, H&Q Healthcare Fund, Qiming Venture Partners, and Vivo Capital. AusperBio is committed to the research and development of functional cure drugs for hepatitis B, leading innovation in oligonucleotide technology.

The funds from this round of financing will be used to rapidly advance the Phase II clinical trial of AusperBio's potential cornerstone drug for hepatitis B cure, AHB-137, as well as exploration of combination therapy regimens and a series of development work including CMC production. Additionally, the financing will also be utilized to expand the proprietary Med-Oligo™ technology platform and its product pipeline.。

According to the introduction, AusperBio is a clinical-stage innovative drug research and development company operating simultaneously in China and the United States. It is committed to developing First-in-class and Best-in-class self-innovative targeted delivery small nucleic acid drugs.AusperBio owns the proprietary intellectual property of the Med-Oligo™ ASO patent technology platform, focusing on functional cures for chronic hepatitis B (HBV) and highly efficient targeted therapies for liver diseases, while also expanding into targeted small nucleic acid treatments for new targets beyond the liver.AusperBio's strategy is to combine its internationally leading Med-Oligo™ oligonucleotide technology with specific and highly efficient targeting technology to address a wide range of currently unmet medical needs.

Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, stated: "We are greatly honored to complete this significant financing under the current market conditions. This financing not only signifies recognition of our R&D achievements but also provides crucial momentum for the next chapter of AusperBio. The successful completion of this financing, along with AHB-137 recently receiving approval from the CDE to be designated as a breakthrough therapy, allows us to further accelerate the clinical development of AHB-137."

Dr. Chengyong Yang, Co-founder and CSO of AusperBio, stated: "We are deeply honored to collaborate with many outstanding investment institutions and sincerely appreciate their support and trust. By integrating cutting-edge oligonucleotide technology with highly efficient and precise targeted delivery systems, AusperBio has successfully developed AHB-137 under our self-developed Med-Oligo™ platform. The Phase I clinical positive data for this drug garnered significant attention at the recent European Association for the Study of the Liver (EASL) Annual Meeting, marking our international leadership in the field of HBV functional cure. This round of financing will further advance the clinical research of AHB-137, benefiting patients worldwide sooner and creating greater value for society."

References

1. AusperBio Official WeChat